Posted by Michael Wonder on 25 Apr 2024
Compass Therapeutics receives FDA fast track designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumours that have been previously treated
25 April 2024 - Compass Therapeutics today announced that the US FDA has granted fast track designation to CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract cancer that have been previously treated.
CTX-009 is a bispecific antibody that simultaneously blocks delta-like ligand 4 and vascular endothelial growth factor A signalling pathways, which are critical to angiogenesis and tumour vascularisation.
